← Back to Search

General improvement for Blood Transfusion

N/A
Waitlist Available
Led By Tyler Anstett, DO
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights

Study Summary

This trial is testing whether improving adherence to guidelines for packed red blood cell transfusions will decrease inappropriate transfusions, and thereby improve patient outcomes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~78 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 78 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Blood Transfusion Orders
Guideline Concordance Measured by Pre-Transfusion Hemoglobin Values Per Transfusion
Other outcome measures
Guideline Concordance Measured by Number of Units Ordered Per Transfusion
Historical Blood Transfusion Orders
Historical Guideline Concordance Measured by Pre-Transfusion Hemoglobin Values Per Transfusion

Trial Design

3Treatment groups
Experimental Treatment
Group I: Interruptive alertExperimental Treatment1 Intervention
In addition to general improvement changes, subjects exposed to the interruptive alert arm receive text detailing evidence-based transfusion recommendations that appear if the most recent hemoglobin level is above 7.0 g/dL. In contrast to the in-line help text arm, this arm includes an interruptive alert that appears when the user selects the transfusion order. This alert offers users the option to remove the order which results in no-blood product ordered. Alternatively, users may continue to order blood and are asked to select the reason for proceeding with the intended order.
Group II: In-line help textExperimental Treatment1 Intervention
In addition to general improvement changes, subjects exposed to the in-line help text arm receive text detailing evidence-based transfusion recommendations that appear if the most recent hemoglobin level is above 7.0 g/dL. This text appears within the transfusion order but is non-interruptive as it does not require users to acknowledge the text nor does is require any additional keystrokes or clicks.
Group III: General improvementExperimental Treatment1 Intervention
Using the expertise of the study personnel, electronic-health record system architects working for UCHealth, and incorporating feedback from the users who participated in the user-centered design sessions we made changes to the blood transfusion order-set as well as the "prepare" and "transfuse" orders. The intention of the changes to the interface are to be more intuitive for ordering clinicians.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
General improvement
2021
N/A
~1640
In-line help text
2021
N/A
~1640
Interruptive alert
2021
N/A
~1640

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,732 Previous Clinical Trials
2,141,943 Total Patients Enrolled
Michael Ho, MD, PhDStudy DirectorUniversity of Colorado Denver Anschutz Medical Campus
1 Previous Clinical Trials
9,501 Total Patients Enrolled
Tyler Anstett, DOPrincipal InvestigatorUniversity of Colorado Denver Anschutz Medical Campus

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Blood Transfusion Reduction - QI Project
2021. "Blood Transfusion Reduction - QI Project". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04823273.
~410 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top